Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.
Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.
Petri
M
M
D015331:Cohort Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology*